Vifor Pharma offers £23m to NHS to resolve CMA investigation
If accepted, Vifor Pharma's £23m offer will "claw back" money for the NHS and close the CMA's first-ever disparagement case.
Corporate Governance
FDA shares new draft guidance for accelerated approval
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
Trump 2.0 could see a rise in biopharmaceutical M&A deals
Trump 2.0 spells global change in pharmaceutical regulation, funding and investment
Dr Oz nominated to lead CMS despite big pharma ties
FDA shares additional draft guidance on CGTs
Trump 2.0 spells uncertainty for US healthcare, says analyst
